false 0001012477 0001012477 2025-03-05 2025-03-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 5, 2025

 

 

 

AVADEL PHARMACEUTICALS PLC

(Exact name of registrant as specified in its charter)

 

 

 

Ireland 001-37977 98-1341933
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

10 Earlsfort Terrace

Dublin 2, Ireland, D02 T380

 

Not Applicable

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: +353 1 901-5201

 

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered

Ordinary Shares, nominal value $0.01 per share

AVDL

 The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

Item 8.01 Other Events.

 

On March 5, 2025, the Compensation Committee (the “Committee”) of the Board of Directors of Avadel Pharmaceuticals plc (the “Company”) approved equity grants consisting of: (i) options to purchase up to 310,000 of the Company’s ordinary shares (“Ordinary Shares”) and 52,000 restricted share awards to Gregory Divis, Chief Executive Officer of the Company; (ii) options to purchase up to 72,000 Ordinary Shares and 12,600 restricted share awards to Thomas McHugh, Chief Financial Officer of the Company; and (iii) options to purchase up to 84,000 Ordinary Shares and 14,700 restricted share awards to Jerad Seurer, General Counsel and Corporate Secretary of the Company. The restricted share awards shall vest in equal annual installments on each of the first four anniversaries following the date of grant, subject in each case to the individual’s continued service at the Company. The options shall vest if at all, as set forth below. Such option awards are performance-based and designed to align with the interests of the Company’s shareholders. To the extent any portion of the options have not vested on or prior to the fifth anniversary of the date of grant, such portion shall expire.

 

Vesting Schedule Description
25% of the shares subject to the option shall vest if the volume-weighted average price of the Company’s Ordinary Shares, as reported by the Nasdaq Global Market, during any 30-calendar day period exceeds $11 per share   Represents a 40% increase in share price from the grant date share price
25% of the shares subject to the option shall vest if the volume-weighted average price of the Company’s Ordinary Shares, as reported by the Nasdaq Global Market, during any 30-calendar day period exceeds $14 per share  Represents a 78% increase in share price from the grant date share price
25% of the shares subject to the option shall vest if the volume-weighted average price of the Company’s Ordinary Shares, as reported by the Nasdaq Global Market, during any 30-calendar day period exceeds $17 per share Represents a 116% increase in share price from the grant date share price
25% of the shares subject to the option shall vest if the volume-weighted average price of the Company’s Ordinary Shares, as reported by the Nasdaq Global Market, during any 30-calendar day period exceeds $19.09 per share Represents a 143% increase in share price from the grant date share price

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AVADEL PHARMACEUTICALS PLC
     
  By: /s/ Jerad G. Seurer
Date: March 7, 2025   Name: Jerad G. Seurer
    Title: General Counsel & Corporate Secretary

 

 

 

v3.25.0.1
Cover
Mar. 05, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 05, 2025
Entity File Number 001-37977
Entity Registrant Name AVADEL PHARMACEUTICALS PLC
Entity Central Index Key 0001012477
Entity Tax Identification Number 98-1341933
Entity Incorporation, State or Country Code L2
Entity Address, Address Line One 10 Earlsfort Terrace
Entity Address, City or Town Dublin 2
Entity Address, Country IE
Entity Address, Postal Zip Code D02 T380
City Area Code 353
Local Phone Number 1 901-5201
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares, nominal value $0.01 per share
Trading Symbol AVDL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Grafico Azioni Avadel Pharmaceuticals (NASDAQ:AVDL)
Storico
Da Mar 2025 a Mar 2025 Clicca qui per i Grafici di Avadel Pharmaceuticals
Grafico Azioni Avadel Pharmaceuticals (NASDAQ:AVDL)
Storico
Da Mar 2024 a Mar 2025 Clicca qui per i Grafici di Avadel Pharmaceuticals